Literature DB >> 10912953

Bovine seminal ribonuclease attached to nanoparticles made of polylactic acid kills leukemia and lymphoma cell lines in vitro.

M Michaelis1, J Matousek, J U Vogel, T Slavik, K Langer, J Cinatl, J Kreuter, D Schwabe, J Cinatl.   

Abstract

Bovine seminal ribonuclease (BS-RNase) is a protein with a number of biological effects. It shows antitumoral, aspermatogenic, antiembryonic, immunosuppressive and antiviral properties. The cytotoxic effects appear to be specific for tumor cells as non-malignant cells seem to be unaffected in vitro. Unfortunately, the in vivo application of BS-RNase so far was successful only when it was administered intratumorally. Therefore, the objective of the present investigation was to improve the properties of BS-RNase by attachment to nanoparticles made of polylactic acid (PLA-NP) using an adsorption method. This preparation was tested in vitro against leukemia (MOLT-4) and lymphoma (H9) cell lines sensitive and resistant to cytarabine. No difference between the nanoparticle preparation and pure BS-RNase was found in these tests. To examine the in vivo effects, the preparations were tested for their aspermatogenic and antiembryonal efficacy compared to the pure BS-RNase as a rapid test for antitumoral activity. The aspermatogenic and antiembryonal effects were enhanced by the nanoparticle preparation. Consequently, BS-RNase loaded adsorptively to PLA-NP holds promise for the in vivo use as an antitumoral agent. Further research will investigate the efficacy of this preparations in an in vivo tumor model.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10912953     DOI: 10.1097/00001813-200006000-00007

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  7 in total

1.  Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery.

Authors:  Huanyu Dou; Christopher J Destache; Justin R Morehead; R Lee Mosley; Michael D Boska; Jeffrey Kingsley; Santhi Gorantla; Larisa Poluektova; Jay A Nelson; Mahesh Chaubal; Jane Werling; James Kipp; Barrett E Rabinow; Howard E Gendelman
Journal:  Blood       Date:  2006-06-29       Impact factor: 22.113

2.  In vitro tagging of embryos with nanoparticles.

Authors:  Tricia L Fynewever; Evelyn S Agcaoili; John D Jacobson; William C Patton; Philip J Chan
Journal:  J Assist Reprod Genet       Date:  2006-12-29       Impact factor: 3.412

3.  Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS.

Authors:  Huanyu Dou; Cassi B Grotepas; JoEllyn M McMillan; Christopher J Destache; Mahesh Chaubal; Jane Werling; James Kipp; Barrett Rabinow; Howard E Gendelman
Journal:  J Immunol       Date:  2009-06-17       Impact factor: 5.422

4.  Development of optical probes for in vivo imaging of polarized macrophages during foreign body reactions.

Authors:  David W Baker; Jun Zhou; Yi-Ting Tsai; Kaitlen M Patty; Hong Weng; Ewin N Tang; Ashwin Nair; Wen-Jing Hu; Liping Tang
Journal:  Acta Biomater       Date:  2014-04-13       Impact factor: 8.947

5.  Incorporation of doxorubicin in different polymer nanoparticles and their anticancer activity.

Authors:  Sebastian Pieper; Hannah Onafuye; Dennis Mulac; Jindrich Cinatl; Mark N Wass; Martin Michaelis; Klaus Langer
Journal:  Beilstein J Nanotechnol       Date:  2019-10-29       Impact factor: 3.649

6.  ABCG2 impairs the activity of the aurora kinase inhibitor tozasertib but not of alisertib.

Authors:  Martin Michaelis; Florian Selt; Florian Rothweiler; Michael Wiese; Jindrich Cinatl
Journal:  BMC Res Notes       Date:  2015-09-28

7.  Doxorubicin-loaded human serum albumin nanoparticles overcome transporter-mediated drug resistance in drug-adapted cancer cells.

Authors:  Hannah Onafuye; Sebastian Pieper; Dennis Mulac; Jindrich Cinatl; Mark N Wass; Klaus Langer; Martin Michaelis
Journal:  Beilstein J Nanotechnol       Date:  2019-08-14       Impact factor: 3.649

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.